口服与长效抗精神病药预防精神分裂症谱系障碍复发的网络荟萃分析
该网络荟萃分析纳入92项随机对照试验共22645名受试者,比较长效注射剂与口服抗精神病药及安慰剂预防复发的效果。绝大多数药物在预防复发上优于安慰剂,其中奥氮平、阿立哌唑和帕利哌酮(长效和口服剂型)表现最佳且证据置信度最高,耐受性方面无药物显著劣于安慰剂但置信度普遍较低。
要点
- 奥氮平、阿立哌唑和帕利哌酮的口服及长效剂型均为预防复发的最佳选择,证据置信度最高。
- 所有纳入抗精神病药在耐受性上均未显著劣于安慰剂,但仅阿立哌唑(长效和口服)有中等置信度。
- 结果可为临床指南及国家与国际药品监管政策提供依据,尤其适用于资源受限地区。
核心结论
- 奥氮平、阿立哌唑和帕利哌酮(长效和口服剂型)是精神分裂症谱系障碍维持治疗预防复发的最佳选择。
研究设计与样本
- 检索Medline、EMBASE、PsycINFO、CENTRAL和CINAHL数据库及在线注册库,纳入截至2021年6月发表的比较长效注射剂或口服抗精神病药头对头或对照安慰剂的随机对照试验。
- 共100项合格试验,其中92项(N=22,645)提供可用数据进行荟萃分析,采用随机效应配对和网络荟萃分析合并相对危险度和标准化均数差,主要结局为复发和因不良事件脱落。
主要发现
- 在预防复发方面,31种纳入治疗中绝大多数优于安慰剂。
- 与安慰剂相比,结果置信度为「高」的药物(按效应量降序)包括:氨磺必利口服、奥氮平口服、阿立哌唑长效、奥氮平长效、阿立哌唑口服、帕利哌酮口服、齐拉西酮口服。
- 与安慰剂相比,结果置信度为「中」的药物包括:帕利哌酮长效1个月剂型、伊潘立酮口服、氟奋乃静口服、布瑞哌唑口服、帕利哌酮长效1个月剂型、阿塞那平口服、氟哌啶醇口服、喹硫平口服、卡利拉嗪口服、鲁拉西酮口服。
- 在耐受性方面,没有抗精神病药显著劣于安慰剂,但置信度低,仅阿立哌唑(长效和口服)显示「中」等置信水平。
关键数值与推荐
- 主要结局为复发和因不良事件脱落。
- 使用Cochrane偏倚风险工具评估研究质量,采用CINeMA方法评估合并估计的置信度。
临床怎么用
- 基于这些发现,奥氮平、阿立哌唑和帕利哌酮是精神分裂症谱系障碍维持治疗的最佳选择,因其长效和口服剂型均为表现最佳的治疗且预防复发的证据置信度最高。
- 该发现对中低收入国家和资源受限环境尤其相关,这些地区可能仅能选择少数药物。
- 该网络荟萃分析的结果可为临床指南及国家和国际药品监管政策提供信息。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
According to current evidence and guidelines, continued antipsychotic treatment is key for preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based recommendations for the choice of the individual antipsychotic for maintenance treatment are lacking. Although oral antipsychotics are often prescribed first line for practical reasons, long-acting injectable antipsychotics (LAIs) are a valuable resource to tackle adherence issues since the earliest phase of disease. Medline, EMBASE, PsycINFO, CENTRAL and CINAHL databases and online registers were searched to identify randomized controlled trials comparing LAIs or oral antipsychotics head-to-head or against placebo, published until June 2021. Relative risks and standardized mean differences were pooled using random-effects pairwise and network meta-analysis. The primary outcomes were relapse and dropout due to adverse events. We used the Cochrane Risk of Bias tool to assess study quality, and the CINeMA approach to assess the confidence of pooled estimates. Of 100 eligible trials, 92 (N=22,645) provided usable data for meta-analyses. Regarding relapse prevention, the vast majority of the 31 included treatments outperformed placebo. Compared to placebo, "high" confidence in the results was found for (in descending order of effect magnitude) amisulpride-oral (OS), olanzapine-OS, aripiprazole-LAI, olanzapine-LAI, aripiprazole-OS, paliperidone-OS, and ziprasidone-OS. "Moderate" confidence in the results was found for paliperidone-LAI 1-monthly, iloperidone-OS, fluphenazine-OS, brexpiprazole-OS, paliperidone-LAI 1-monthly, asenapine-OS, haloperidol-OS, quetiapine-OS, cariprazine-OS, and lurasidone-OS. Regarding tolerability, none of the antipsychotics was significantly worse than placebo, but confidence was poor, with only aripiprazole (both LAI and OS) showing "moderate" confidence levels. Based on these findings, olanzapine, aripiprazole and paliperidone are the best choices for the maintenance treatment of schizophrenia-spectrum disorders, considering that both LAI and oral formulations of these antipsychotics are among the best-performing treatments and have the highest confidence of evidence for relapse prevention. This finding is of particular relevance for low- and middle-income countries and constrained-resource settings, where few medications may be selected. Results from this network meta-analysis can inform clinical guidelines and national and international drug regulation policies.
引用
- Ostuzzi G, Bertolini F, Tedeschi F, et al. Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants. World Psychiatry. 2022. PMID: 35524620. doi:10.1002/wps.20972
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。